Silence Therapeutics PLC (LON:SLN, NASDAQ:SLN) said its medics and scientist has contributed to a peer-reviewed paper that explores the “promising potential” RNA interference (RNAi) therapies for treating heart disease.
RNAi is a natural process that works almost like a dimmer switch to dial down the level of a protein.
The study carried in the European Society of Cardiology’s research journal focuses on the use of RNAi in lowering elevated levels of lipoprotein (a) (Lp(a)).
As Silence’s chief medical officer Giles Campion points out, there is a growing body of evidence pointing to high Lp(a) as a “key predeterminant of cardiovascular disease”, including premature heart attack and stroke.
Unlike high cholesterol, levels of which can be modified through diet and statins, Lp(a) is genetic and therefore isn’t affected by alterations to lifestyle.
“When considering a potential long-term preventative treatment for a large population, Lp(a)-lowering therapy must be safe, effective, well-tolerated and conveniently administered,” said Campion.
“Our review explores the promising potential of RNAi therapies to fit that profile and address a major unmet need in cardiovascular disease.”
For more information click here.